鞍山地区2013年1月～2018年1月血友病诊疗的临床回顾分析(3)
[8]Mahlangu J，Powell JS，Ragni MV，et al.Phase 3 study of recombinant factor Ⅷ Fc fusion protein in severe hemophilia A[J].Blood，2014，123(3)：317-325.
[9]Martinowitz U，Lissitchkov T，Lubetsky A，et al.Results of aphase Ⅰ/Ⅱ open-label，safety and effi cacy trial of coagulation factor Ⅸ (recombinant)，albumin fusion protein in haemophilia bpatients[J].Haemophilia，2015，21(6)：784-790.
[10]Ingerslev J，Sorensen B.Parallel use of bypassing agents in haemophilia with inhibitors：a critical review[J].Br J Haematol，2011，155(2)：256-262.
[11]Saenko EL，Pipe SW.Strategies towards a longer acting factor Ⅷ[J].Haemophilia，2006，12(Suppl 3)：42-51
[12]Spencer HT，Riley BE，Doering CB.State of the art：gene therapy of haemophilia[J].Haemophilia，2016，22(Suppl 5)：66-71.
[13]Fomin ME，Togarrati PP，Muench MO.Progress and challenges in the development of a cell-based therapy for hemophilia A[J].J Thromb Haemost，2014，12(12)：1954-1965.
[14]Guan Y，Ma Y，Li Q，et al.CRISPR/Cas9-mediated somatic correction of a novel coagulator factor Ⅸ gene mutation ameliorates hemophilia in mouse[J].EMBO Mol Med 2016，8(5)：477-488.
[15]Davidoff AM，Nathwani AC.Genetic targeting of the albumin locus to treat hemophilia[J].N Engl J Med，2016，374(13)：1288-1290.
(收稿日期：2018-03-22 本文編辑：闫 佩), http://www.100md.com(闫朝奇 冷青 由国平)
[9]Martinowitz U，Lissitchkov T，Lubetsky A，et al.Results of aphase Ⅰ/Ⅱ open-label，safety and effi cacy trial of coagulation factor Ⅸ (recombinant)，albumin fusion protein in haemophilia bpatients[J].Haemophilia，2015，21(6)：784-790.
[10]Ingerslev J，Sorensen B.Parallel use of bypassing agents in haemophilia with inhibitors：a critical review[J].Br J Haematol，2011，155(2)：256-262.
[11]Saenko EL，Pipe SW.Strategies towards a longer acting factor Ⅷ[J].Haemophilia，2006，12(Suppl 3)：42-51
[12]Spencer HT，Riley BE，Doering CB.State of the art：gene therapy of haemophilia[J].Haemophilia，2016，22(Suppl 5)：66-71.
[13]Fomin ME，Togarrati PP，Muench MO.Progress and challenges in the development of a cell-based therapy for hemophilia A[J].J Thromb Haemost，2014，12(12)：1954-1965.
[14]Guan Y，Ma Y，Li Q，et al.CRISPR/Cas9-mediated somatic correction of a novel coagulator factor Ⅸ gene mutation ameliorates hemophilia in mouse[J].EMBO Mol Med 2016，8(5)：477-488.
[15]Davidoff AM，Nathwani AC.Genetic targeting of the albumin locus to treat hemophilia[J].N Engl J Med，2016，374(13)：1288-1290.
(收稿日期：2018-03-22 本文編辑：闫 佩), http://www.100md.com(闫朝奇 冷青 由国平)